Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: Comparison with the corresponding antibody-enzyme conjugate

Pharmaceutical Research

Volumn 20, Issue 3, 2003, Pages 423-428

  Fonseca, María José ^a   Jagtenberg, Joycelyn C ^a   Haisma, Hidde J ^b,c   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

(Immuno)liposomes; Antibody directed enzyme prodrug therapy (ADEPT); Antibody enzyme conjugate; Enzyme targeting; Enzymosomes; Prodrug activation

Indexed keywords

BETA GLUCURONIDASE; DOXORUBICIN DERIVATIVE; ENZYME; GLUCURONIDE; IMMUNOGLOBULIN F(AB) FRAGMENT; LIPOSOME; MONOCLONAL ANTIBODY; PRODRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IN VITRO STUDY; INCUBATION TIME; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; GLUCURONIC ACIDS; GLUCURONIDASE; HUMANS; LIPOSOMES; MICE; PRODRUGS;

EID: 0037338049     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022608321861     Document Type: Article

References (16)

1. G. Storm, M. H. Vingerhoeds, D. J. A. Crommelin, and H. J. Haisma. Immunoliposomes bearing enzymes (immunoenzymosomes) for site-specific activation of anticancer prodrugs. Adv. Drug Deliv. Rev. 24:225-231 (1997).
2. R. G. Leenders, E. W. Damen, E. J. Bijsterveld, H. W. Scheeren, P. H. J. Houba, I. H. van der Meulen-Mulleman, E. Boven, and H. J. Haisma. Novel anthracycline-spacer-beta-glucuronide, -beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy. Bioorg. Med. Chem. 7:1597-1610 (1999).
3. P. H. J. Houba, E. Boven, I. H. van der Meulen-Mulleman, R. G. G. Leenders, J. W. Scheeren, H. M. Pinedo, and H. J. Haisma. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br. J. Cancer 84:550-557 (2001).
4. T. C. Hamilton, R. C. Young, W. M. Mc Koy, K. R. Grotzinger, J. A. Green, E. W. Chu, J. Whang-Penn, A. M. Rogan, W. R. Green, and R. F. Ozols. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43:5379-5389 (1983).
5. M. J. Fonseca, H. J. Haisma, S. Klaassen, M. H. Vingerhoeds, and G. Storm. Design of immuno-enzymosomes with maximum enzyme targeting capability: Effect of the enzyme density on the enzyme targeting capability and cell binding properties. Biochim. Biophys. Acta 1419:272-282 (1999).
6. H. J. Haisma, E. Boven, M. v. Muijen, J. Jong, W. J. F. v. d. Vijgh, and H. M. Pinedo. A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer 66:474-478 (1992).
7. D. Wessel and U. I. Flügge. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem. 138:141-143 (1984).
8. U. K. Nässander, P. A. Steerenberg, W. H. de Jong, W. O. W. M. van Overveld, C. M. E. te Boekhorst, L. G. Poels, P. H. K. Jap, and G. Storm. Design of immunoliposomes directed against human ovarian carcinoma. Biochim. Biophys. Acta 1235:126-139 (1995).
9. G. Rouser, S. Fleisner, and A Yamamoto. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5:494-496 (1970).
10. M. H. Vingerhoeds, H. J. Haisma, M. v. Muijen, R. B. J. v. d. Rijt, D. J. A. Crommelin, and G. Storm. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Lett. 3:485-490 (1993).
11. M. H. Vingerhoeds, H. J. Haisma, S. O. Belliot, R. J. P. Smit, D. J. A. Crommelin, and G. Storm. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): Optimization of prodrug activating capacity. Pharm. Res. 13:604-610 (1996).
12. M. J. Fonseca, G. Storm, W. E. Hennink, W. R. Gerritsen, and H. J. Haisma. Cationic polymeric gene delivery of β-glucuronidase for doxorubicin prodrug therapy. J. Gene Med. 1:407-414 (1999).
13. K. D. Bagshawe, S. K. Sharma, C. J. Springer, and P. Antoniw. Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumor Targeting 1:17-29 (1995).
14. J. Martin, S. M. Stribbling, G. K. Poon, R. H. J. Begent, M. Napier, S. K. Sharma, and C. J. Springer. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother. Pharmacol. 40:189-201 (1997).
15. K. N. Syringos and A. A. Epenetos. Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations. Anticancer Res. 19:605-614 (1999).
16. P. H. J. Houba, R. G. G. Leenders, E. Boven, J. W. Scheeren, H. M. Pinedo, and H. J. Haisma. Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem. Pharmacol. 52:45-63 (1996).